Acridine carboxamide

From Wikipedia, the free encyclopedia

Acridine carboxamide (N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide) is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

While the agent was well-tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]

[edit] References

  1. ^ Dittrich C, Dieras V, Kerbrat P, et al (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs 21 (3): 347–52. PMID 14578683. 
  2. ^ Caponigro F, Dittrich C, Sorensen JB, et al (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer 38 (1): 70–4. PMID 11750842. 
  3. ^ Twelves C, Campone M, Coudert B, et al (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. PMID 12075748. 
  4. ^ Dittrich C, Coudert B, Paz-Ares L, et al (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer 39 (3): 330–4. PMID 12565985.